Live Breaking News & Updates on High Grade Serous Ovarian
Stay updated with breaking news from High grade serous ovarian. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Updated data from azenosertib monotherapy study with longer follow up shows 37% ORR and mPFS of 6.5 months in heavily pretreated ovarian and uterine serous carcinoma patients Azenosertib programs on. ....
A case study on how a leading midcap oncology-focused company utilized DelveInsight's Conference Coverage Service to get real-time and exhaustive insights. The information revolved around next-generation ....